首页> 外文期刊>BMC research notes >Radiotherapy of nasopharyngeal cancer using Rapidarc: dosimetric study of military teaching hospital Mohamed V, Morocco
【24h】

Radiotherapy of nasopharyngeal cancer using Rapidarc: dosimetric study of military teaching hospital Mohamed V, Morocco

机译:使用Rapidarc进行鼻咽癌放疗:摩洛哥穆罕默德五世军事教学医院的剂量学研究

获取原文
           

摘要

BackgroundThe aim of the present study is to assess efficacy and efficiency of Volumetric-modulated arc therapy (VMAT) technique in treatment of nasopharyngeal cancer in our institution and to report toxicity related to this technique. MethodsBetween June 2013 and January 2015, thirty-two patients with non metastatic nasopharyngeal cancer were curatively treated using VMAT Rapidarc. Dose prescription was performed using two different schedules, it consisted of either simultaneous integrated boost or simultaneous modulated accelerated radiation therapy delivering 70?Gy in 35 fractions and 69.96 in 33 fractions respectively. The choice was leaved at the discretion of the treating physician. The optimization process was performed by Eclipse software version 10.0 (Varian Medical Systems), using PRO algorithm (Progressive resolutive optimisation) version 3. Data was collected from dose-volume histograms for both planning target volumes (PTV) and organs at risk (OAR). We calculated the homogeneity index and the conformity index as well as the number of monitor units MU and the treatment delivery time. We also reported acute and late toxicity related to radiation therapy. ResultsFor the PTV high risk (HR), intermediate risk (PTV IR) and low risk (LR) the D95% was 97.21?±?1.5, 97.5?±?3.3 and 97.10?±?6.86 respectively. Whereas, The D5% was 104.6?±?2.16, 103.8?±?2.1 and 100.89?±?7.26. The CI for PTV HR was 0.98?±?0.02 and the HI was 0.08?±?0.02. The mean treatment delivery time was 2.3?±?0.2, and the mean MU number was 527.6?±?131.4. Grade 4 toxicity was not reported in any case. Grade 3 xerostomia was observed in only 3(9.4%) patients and no patients developed grade 3 hearing loss. ConclusionOur results confirmed the abilities of VMAT to provide excellent coverage of target volumes while sparing OAR especially the nervous structures and salivary glands.
机译:背景技术本研究的目的是评估容积调制弧光治疗(VMAT)技术在我们机构中治疗鼻咽癌的疗效和效率,并报告与该技术相关的毒性。方法在2013年6月至2015年1月期间,使用VMAT Rapidarc对32例非转移性鼻咽癌患者进行了治愈。剂量处方使用两种不同的方案进行,包括同时联合加强免疫或同时调制加速放射治疗,分别以35份和70.Gy分33份分送。选择权由主治医师决定。优化过程是通过Eclipse软件版本10.0(Varian Medical Systems)和PRO算法(渐进分辨优化)版本3进行的。从剂量体积直方图中收集了计划目标体积(PTV)和危险器官(OAR)的数据。 。我们计算了均一性指数和合格指数以及监测器单元MU的数量和治疗时间。我们还报告了与放射治疗有关的急性和晚期毒性。结果PTV高危(HR),中危(PTV IR)和低危(LR)的D95%分别为97.21±1.5、97.5±3.3和97.10±6.86。而D5为104.6±2.16、103.8±2.1和100.89±7.26。 PTV HR的CI为0.98±±0.02,HI为0.08±±0.02。平均治疗分娩时间为2.3±±0.2,平均MU数为527.6±±131.4。在任何情况下均未报告4级毒性。仅3名(9.4%)患者观察到3级口干燥症,没有患者出现3级听力损失。结论我们的结果证实了VMAT能够出色地覆盖目标体积,同时又能节省OAR(尤其是神经结构和涎腺)的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号